Edelstein Charles L
Division of Renal Diseases, University of Colorado Health Sciences Center, Denver, CO 80262, USA.
Adv Chronic Kidney Dis. 2008 Jul;15(3):222-34. doi: 10.1053/j.ackd.2008.04.003.
The diagnosis of acute kidney injury (AKI) is usually based on measurements of blood urea nitrogen (BUN) and serum creatinine. BUN and serum creatinine are not very sensitive or specific for the diagnosis of AKI because they are affected by many renal and nonrenal factors that are independent of kidney injury or kidney function. Biomarkers of AKI that are made predominantly by the injured kidney have been discovered in preclinical studies. In clinical studies of patients with AKI, some of these biomarkers (eg, interleukin-18, neutrophil gelatinase-associated lipocalin, and kidney injury molecule-1) have been shown to increase in the urine before the increase in serum creatinine. These early biomarkers of AKI are being tested in different types of AKI and in larger clinical studies. Biomarkers of AKI may also predict long-term kidney outcomes and mortality.
急性肾损伤(AKI)的诊断通常基于血尿素氮(BUN)和血清肌酐的测定。BUN和血清肌酐对AKI的诊断并非非常敏感或特异,因为它们受许多与肾损伤或肾功能无关的肾脏和非肾脏因素影响。在临床前研究中已发现主要由受损肾脏产生的AKI生物标志物。在AKI患者的临床研究中,已表明其中一些生物标志物(如白细胞介素-18、中性粒细胞明胶酶相关脂质运载蛋白和肾损伤分子-1)在血清肌酐升高之前尿中就已升高。这些AKI的早期生物标志物正在不同类型的AKI以及更大规模的临床研究中进行测试。AKI生物标志物还可能预测长期肾脏转归和死亡率。